Biocon Latest Updates

Biosimilar Approvals and Launches: Biocon Biologics received Health Canada approval for Yesafili™ (aflibercept), a biosimilar to Eylea®, on June 26, 2025. This marks the first biosimilar to Eylea approved in Canada, with a launch planned for July 4, 2025. This will be their 10th biosimilar commercialized globally. They also secured EU approval for generic diabetes and weight management drugs (Victoza and Saxenda) and gained Indian approval for Liraglutide. Financial & Corporate Moves: Biocon Limited successfully completed a Qualified Institutions Placement (QIP) on June 20, 2025, raising Rs 4,500 crore (USD 523 million) to strengthen its balance sheet and support growth. There are ongoing discussions about a potential merger with its subsidiary, Biocon Biologics. Strategic Decisions & Regulatory Updates: Biocon has decided to drop plans for launching generic versions of Ozempic and Wegovy in China due to intense local competition. Regarding regulatory inspections, Biocon received four observations from the USFDA for its Bengaluru API facility in September 2024 and for its Andhra Pradesh facility in June 2024.